New Tuberculosis Drug Development

This publication has 18 references indexed in Scilit:

• Rifapentine and Isoniazid in the Continuation Phase of Treating Pulmonary Tuberculosis
  American Journal of Respiratory and Critical Care Medicine, 1998
• The Clinical Use of Fluoroquinolones for the Treatment of Mycobacterial Diseases
  Clinical Infectious Diseases, 1997
• Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis.
  American Journal of Respiratory and Critical Care Medicine, 1996
• A Randomized Trial of Clarithromycin as Prophylaxis against DisseminatedMycobacterium aviumComplex Infection in Patients with Advanced Acquired Immunodeficiency Syndrome
  New England Journal of Medicine, 1996
• Prophylaxis against DisseminatedMycobacterium aviumComplex with Weekly Azithromycin, Daily Rifabutin, or Both
  New England Journal of Medicine, 1996
• Randomized Controlled Trial of a Drug Regimen That Includes Ciproftoxacin for the Treatment of Pulmonary Tuberculosis
  Clinical Infectious Diseases, 1996
• In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR3355)
  Tubercle and Lung Disease, 1995
• Clarithromycin Therapy for BacteremicMycobacterium aviumComplex Disease
  Annals of Internal Medicine, 1994
• Two Controlled Trials of Rifabutin Prophylaxis against Mycobacterium avium Complex Infection in AIDS
  New England Journal of Medicine, 1993
• Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice
  Antimicrobial Agents and Chemotherapy, 1993